Skip to main content
Log in

Development of New Prolactin Analogs Acting as Pure Prolactin Receptor Antagonists

Pituitary Aims and scope Submit manuscript

Abstract

Prolactin (PRL) promotes tumor growth, as recently highlighted by the spontaneous appearance of prostate hyperplasia and mammary neoplasia in PRL transgenic mice. Increasing experimental evidence argues for the involvement of autocrine PRL in this process. Human (h)PRL receptor antagonists have been developed to counteract these undesired proliferative actions of PRL. However, all PRL receptor antagonists obtained to date exhibit partial agonism, limiting their therapeutic use as full antagonists. This is the case for the first generation antagonists (the prototype of which is G129R-hPRL) that we developed ten years ago, which display antagonistic activity in some, but not all in vitro bioassays, and fail to inhibit PRL activity in transgenic mice expressing this analog. We recently developed new human PRL antagonists devoid of agonistic properties, and therefore able to act as pure antagonists. This was demonstrated using several in vitro bioassays, including assays able to detect extremely low levels of receptor activation. These new compounds also act as pure antagonists in vivo, as demonstrated by their ability to competitively inhibit PRL-triggered signaling cascades in various target tissues (liver, mammary gland and prostate). Finally, using transgenic mice specifically expressing PRL in the prostate, which have constitutively activated signaling cascades and prostate hyperplasia, these new PRL analogs are able to completely revert PRL-activated events to basal levels. These second generation antagonists are good candidates to be used as inhibitors of the growth-promoting actions of hPRL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. EndocrRev 2003;24:1-27.

    Google Scholar 

  2. Wennbo H, Tornell J. The role of prolactin and growth hormone in breast cancer. Oncogene 2000;19:1072-1076.

    Google Scholar 

  3. Vomachka AJ, Pratt SL, Lockefeer JA, Horseman ND. Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 2000;19:1077-1084.

    Google Scholar 

  4. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 1997;100:2744-2751.

    Google Scholar 

  5. Wang DY, De Stavola BL, Bulbrook RD, et al. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 1992;21:214-221.

    Google Scholar 

  6. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE. Aprospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 2000,9:575-579.

    Google Scholar 

  7. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prey 1994;18:79-85.

    Google Scholar 

  8. Hankinson SE, Willett WC, Michaud DS, et al. Plasmaprolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:629-634.

    Google Scholar 

  9. Touraine P, Martini JF, Zafrani B, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 1998;83:667-674.

    Google Scholar 

  10. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997;138:5555-5560.

    Google Scholar 

  11. Mertani HC, Garcia-Caballero T, Lambert A, et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer 1998;79:202-211.

    Google Scholar 

  12. Brockman JL, Schroeder MD, Schuler LA. PRL activates the cyclin D 1 promoter via the Jak2/Stat pathway. Mol Endocrinol 2002;16:774-784.

    Google Scholar 

  13. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-1021.

    Google Scholar 

  14. Brisken C, Ayyannan A, Nguyen C, et al. IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell 2002;3:877-887.

    Google Scholar 

  15. Sciacca L, Costantino A, Pandini G, et al. Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism. Oncogene 1999;18:2471-2479.

    Google Scholar 

  16. Anderson E, Ferguson JE, Morten H, Shalet SM, Robinson EL, Howell A. Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. Eur J Cancer 1993;29A:209-217.

    Google Scholar 

  17. Bonneterre J, Mauriac L, Weber B, et al. Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer. Results of a double blind multicentre clinical trial. Eur J Cancer Clin Oncol 1988;24:1851-1853.

    Google Scholar 

  18. Manni A, Boucher AE, Demers LM, et al. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 1989; 14:289-298.

    Google Scholar 

  19. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: Distribution, regulation, functions, and clinical aspects. Endocr Rev 1996;17:639-669.

    Google Scholar 

  20. Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995;55:2591-2595.

    Google Scholar 

  21. Clevenger CV, Chang WP, Ngo W, Pasha TM, Montone KT, Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma. Am J Pathol 1995; 146:695-705.

    Google Scholar 

  22. Mershon J, Sall W, Mitchner N, Ben-Jonathan N. Prolactin is a local growth factor in rat mammary tumors. Endocrinology 1995;136:3619-3623.

    Google Scholar 

  23. Clevenger CV, Plank TL. Prolactin as an autocrine/paracrine factor in breast cancer. J Mammary Gland Biol Neopl 1997;2:59-68.

    Google Scholar 

  24. Llovera M, Touraine P, Kelly PA, Goffin V. Involvement of prolactin in breast cancer: Redefining the molecular targets. Exp Gerontol 2000;35:41-51.

    Google Scholar 

  25. Ben Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Irends Endocrinol Metab 2002;13:245-250.

    Google Scholar 

  26. Kindblom J, Dillner K, Sahlin L et al. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 2003;144:2269-2278.

    Google Scholar 

  27. Kindblom J, Dillner K, Ling C, Tornell J, Wennbo H. Progressive prostate hyperplasia in adult prolactin transgenic mice is not dependent on elevated serum androgen levels. Prostate 2002;53:24-33.

    Google Scholar 

  28. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ER?-positive and ER?-negative mammary cancer in transgenic mice. Oncogene 2003;22(30):4664-4674.

    Google Scholar 

  29. Baudhuin A, Manfroid I, Van De WC, Martial JA, Muller M. Transcription of the human prolactin gene in mammary cells. Ann NY Acad Sci 2002;973:454-458.

    Google Scholar 

  30. Goffin V, Kelly PA. The prolactin/growth hormone receptor family Structure/function relationships. J Mammary Gland Biol Neopl 1997;2:7-17.

    Google Scholar 

  31. Goffin V, Shiverick KT, Kelly PA, Martial JA. Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocr Rev 1996;17:385-410.

    Google Scholar 

  32. Kinet S, Bernichtein S, Llovera M, KellyPA, Martial JA, Goffin V. Molecular basis of the interaction between human prolactin and its membrane receptor: A ten year study. Recent Res Devel Endocrinol 2001;2:1-24.

    Google Scholar 

  33. Wells JA. Binding in the growth hormone receptor complex. Proc Natl Acad Sci USA 1996;93:1-6.

    Google Scholar 

  34. Frank SJ. Minireview: Receptor dimerization in GH and erythropoietin action—It takes two to tango, but how? Endocrinology 2002;143:2-10.

    Google Scholar 

  35. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science 1992;256:1677-1680.

    Google Scholar 

  36. Goffin V, Struman I, Mainfroid V, Kinet S, Martial JA. Evidence for a second receptor binding site on human prolactin. J Biol Chem 1994;269:32598-32606.

    Google Scholar 

  37. Goffin V, Kinet S, Ferrag F, Binart N, Martial JA, Kelly PA. Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. J Biol Chem 1996;271:16573-16579.

    Google Scholar 

  38. Fuh G, Wells JA. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem 1995;270:13133-13137.

    Google Scholar 

  39. Llovera M, Pichard C, Bernichtein S, et al. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 2000;19:4695-4705.

    Google Scholar 

  40. Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE. Ahuman prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin Cancer Res 1999;5:3583-3593.

    Google Scholar 

  41. Beck MT, Peirce SK, Chen WY. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene 2002;21:5047-5055.

    Google Scholar 

  42. Cataldo L, Chen NY, Yuan Q, et al. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells. Int J Oncol 2000;17:1179-1185.

    Google Scholar 

  43. Chen NY, Holle L, Li W, Peirce SK, Beck MT, Chen WY. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R. Int J Oncol 2002;20813-818.

  44. Kinet S, Bernichtein S, Kelly PA, Martial JA, Goffin V. Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites. J Biol Chem 1999;274:26033-26043.

    Google Scholar 

  45. Bernichtein S, Jeay S, Vaudry R, Kelly PA, Goffin V. New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity. Endocrine 2003;20:177-190.

    Google Scholar 

  46. Ormandy CJ, Camus A, BarraJ, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 1997;11:167-178.

    Google Scholar 

  47. Chen TJ, Kuo CB, Tsai KF, Liu JW, Chen DY, Walker AM. Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology 1998;139:609-616.

    Google Scholar 

  48. Bernichtein S, Kinet S, Jeay S, et al. S179D-hPRL, a pseudophosphorylated human prolactin analog, is an agonist and not an antagonist. Endocrinology 2001; 142:3950-3963.

    Google Scholar 

  49. Bernichtein S, Jomain J-B, Kelly PA, Goffin V. The N-terminus of human prolactin modulates its biological properties. Mol Cel Endocrinol 2003, in press.

  50. Bernichtein S, Kayser C, Dillner K, Kopchick JJ, Isaksson OGP, Norstedt G, Martial JA, Kelly PA, Goffin V. Development of pure prolactin antagonists. J Biol Chem 2003;278(38):35988-35999.

    Google Scholar 

  51. Goffin V, Bernichtein S, Carriere O, Bennett WF, Kopchick JJ, Kelly PA. The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology 1999;140:3853-3856.

    Google Scholar 

  52. Kaulsay KK, Zhu T, Bennett W, Lee K, Lobie PE. The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology 2001;142:767-777.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goffin, V., Bernichtein, S., Kayser, C. et al. Development of New Prolactin Analogs Acting as Pure Prolactin Receptor Antagonists. Pituitary 6, 89–95 (2003). https://doi.org/10.1023/B:PITU.0000004799.41035.9f

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:PITU.0000004799.41035.9f

Navigation